SCHEMBL5810397

SCHEMBL5810397

Nc1c(C(=O)O)nnc2cc(Cl)c(F)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.40
MAP2K3 P46734 1/20 0.40
MAP2K6 P52564 1/20 0.40
BTK Q06187 1/20 0.40
MAP3K19 Q56UN5 1/20 0.40
NEK10 Q6ZWH5 1/20 0.40
PTGS2 P35354 2/20 0.39
LRRK2 Q5S007 4/20 0.37
MDM2 Q00987 2/20 0.35
ALPL P05186 1/20 0.35
KMO O15229 2/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
LMNA P02545 1/20 0.34
GRIK1 P39086 1/20 0.34
GRIA1 P42261 1/20 0.34
GRIA2 P42262 1/20 0.34
GRIA3 P42263 1/20 0.34
GRIA4 P48058 1/20 0.34
GRIN1 Q05586 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5807279 0.88 LCK (0.50) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL20843885 0.69 LCK (0.49) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL9496321 0.68 LCK (0.77) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL20839022 0.67 BTK (0.50) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL27728270 0.66 EGFR (0.46) ALPLKMOLMNAEGLN1HAVCR2
SCHEMBL2909586 0.65 IGFBP5 (0.46) ALPLKMOEGLN1GRM2
SCHEMBL31450095 0.64 GABRG2 (0.43) LCKMAP2K3MAP2K6BTKMAP3K19
SCHEMBL9592356 0.64 EGFR (0.45) ALPLEGLN1HAVCR2
SCHEMBL406782 0.63 KEAP1 (0.50) TDP1
SCHEMBL1096218 0.63 KEAP1 (0.50) ALPLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060264439-A1 Inhibitors of polo-like kinase-1 SUPERGEN, INC. (US) 2006-11-23 US disclosed
WO-2006124996-A2 INHIBITORS OF POLO-LIKE KINASE-1 SUPERGEN, INC. (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264439-A1 Inhibitors of polo-like kinase-1 PLK2, PHKG1, PRKDC LCK 425/4885MAP2K3 391/4885MAP2K6 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.